Glucagon-like peptide-1 oral transmucosal - Watson

Drug Profile

Glucagon-like peptide-1 oral transmucosal - Watson

Latest Information Update: 11 Apr 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Watson Laboratories
  • Class Glucagon-like peptides
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 14 May 2003 Watson Laboratories is seeking a partner to develop and commercialise the product worldwide (
  • 14 May 2003 No development reported - Phase-I for Type-2 diabetes mellitus in USA (Transmucosal)
  • 16 Jan 2001 TheraTech is now called Watson Laboratories
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top